Abcam, ab15160, Anti-Chromogranin A antibody

Size: 100µL / 500µL / 1mL
Anti-Chromogranin A antibody (ab15160) is a rabbit polyclonal antibody detecting Chromogranin A in IHC-P . Suitable for Human . - Over 230 publications - Trusted since 2004
Key facts
Host species:Rabbit,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Product Specifications
Anti-Chromogranin A antibody (ab15160) is a rabbit polyclonal antibody and is validated for use in IHC-P in human samples.
Anti-Chromogranin A antibody (ab15160) specifically detects Chromogranin A (UniProt ID: P10645; Molecular weight: 49kDa) and is sold in 100 µL, 500 µL and 1 mL selling sizes.
Quality and Validation
Abcam's high quality validation processes ensure Anti-Chromogranin A antibody (ab15160) has high sensitivity and specificity.
Anti-Chromogranin A antibody (ab15160) has been cited over 238 times in peer reviewed journals and is trusted by the scientific community.
Anti-Chromogranin A antibody (ab15160) has 29 independent reviews from customers.
Target Information
Chromogranin A (CgA) or parathyroid secretory protein 1 is encoded in the human by the gene CHGA. Chromogranin A (CgA) is found in the secretory vesicles of neuroendocrine cells and serves as a key biomarker in oncology. It is particularly useful in diagnosing and monitoring neuroendocrine tumors (NETs).

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Immunogen, Storage buffer-pH: 7.6Preservative: 0.1% Sodium azideConstituents: PBS, 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Chromogranin A (CgA) sometimes called chromagranin A is a glycoprotein with a molecular weight of approximately 49–52 kDa. It is highly expressed in the secretory granules of neuroendocrine cells present in tissues such as the adrenal medulla pancreas and endocrine cells of the gastrointestinal tract. CgA identified as part of a family including chromogranin B and chromogranin C functions mechanically as a precursor to various bioactive peptides. This translates into its involvement in the storage and release of hormones and peptides within vesicles.
Biological function summary
Chromogranin A assists in the regulation of secretory pathways across multiple neuroendocrine systems. It plays a role in hormone storage conversion to active peptides and regulates the exocytosis of hormones. CgA acts within a complex contributing to secretory granule biogenesis and influencing intravesicular acidity. As a regulatory component the exact physiological roles are diverse impacting cardiovascular metabolic and immunological processes.
Pathways
Chromogranin A is involved in pathways such as the catecholamine synthesis and release pathway and the serotonergic pathway. Within these pathways it interacts with proteins like secretogranin II and parathyroid hormone (PTH). These interactions modulate neurotransmitter storage and secretion across various systems. CgA's bioactive peptides also contribute to modulating physiological processes like vasoconstriction and insulin regulation linking it closely with these signaling cascades.
Chromogranin A is a known marker for neuroendocrine tumors where its levels in blood may increase due to tumor activity. It links to diseases like pheochromocytoma and carcinoid tumors where improper regulation of CgA-associated pathways occurs. Additionally its connection to parathyroid disorders through the PTH pathway illustrates its broader implication in endocrine pathophysiology. CgA serves as an invaluable diagnostic and prognostic tool in these disease states and supports the development of targeted therapies.